In addition to following your doctor’s recommendations for prostate cancer screening, pay close attention to the symptoms ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

By Dr Wendy Winnall - PCFA Research TeamA recent prostate cancer study from Canada has received a lot of publicity. This study measured the risk of ...

1 Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology ...

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 ...

Yesterday, the FDA approved niraparib and abiraterone acetate (Akeega; Janssen) with prednisone (AAP) for adults with certain prostate cancers—namely those with “deleterious or suspected deleterious ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn’t leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. “I wasn’t someone ...

LONDON, Dec 10 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared with standard endocrine ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader (SERD) to a 30% reduction in the risk of invasive disease ...

A month after my annual physical, I found a lump in my breast. I was initially diagnosed with stage 3 triple-negative breast cancer (a rare type that lacks receptors for estrogen, progesterone, and ...